Development of a stacking model for personalized treatment of Crohn’s disease: leveraging routine clinical features to forecast infliximab response

AimsInfliximab (IFX) is widely used for treating Crohn’s disease (CD), but a significant proportion of patients experience primary non-response or loss of response. Early prediction of IFX efficacy is crucial to avoid ineffective treatment, adverse effects, and financial burden. The aim of this study was to develop a stacking model using routine clinical data to predict IFX clinical response.MethodThis retrospective cohort study enrolled CD patients initiating IFX therapy between January 2019 an